Clinical Note
September 2006

Antenatal Carbimazole and Choanal AtresiaA New Embryopathy

Author Affiliations

Author Affiliations: Department of Otolaryngology, St George's Hospital, Tooting, London (Messrs Wolf and Daya), and Department of Genetics, Southampton University Hospital, Southampton (Dr Foulds), England.


Copyright 2006 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2006

Arch Otolaryngol Head Neck Surg. 2006;132(9):1009-1011. doi:10.1001/archotol.132.9.1009

Carbimazole embryopathy is a recently recognized and defined phenotype. Choanal atresia; gastrointestinal anomalies, particularly esophageal atresia; athelia or hypothelia; developmental delay; hearing loss; aplasia cutis; and dysmorphic facial features all can occur after exposure to the antithyroid drugs carbimazole or methimazole during gestation. Although full expression of this phenotype appears to be an uncommon sequelae of antenatal carbimazole exposure, infants with less overt manifestations may remain with the condition undiagnosed. It is clearly important when an infant with choanal atresia is assessed to take an adequate drug history and consider this embryopathy as a potential causative factor.